Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial. The biotech is planning to launch a late-stage program for the drug later ...

The three-dimensional structure of a protein underpins its biological function, making structure determination and prediction central challenges in structural biology. Although experimental techniques ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. After the ...

A structure-aware skeleton generator that mirrors your rendered UI at runtime. Automatically generates responsive shimmer states with zero layout duplication. Built for React, Vue, Angular, Svelte and ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Structure Therapeutics ...

Just two of the nine shoes leading Nike’s reorganized running lineup have yet to release. Both of those come from the Structure franchise, and one has been confirmed for an early 2026 release. The ...